Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 9.49M 11.89M |
---|---|---|---|---|---|
Net income 2023 * | -11M -13.78M | Net income 2024 * | -17M -21.29M | EV / Sales 2023 * | - |
Net Debt 2023 * | 10.76M 13.48M | Net Debt 2024 * | 28.9M 36.2M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.65
x | P/E ratio 2024 * |
-0.45
x | Employees | 17 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 63.35% |
1 month | +2.22% | ||
6 months | -4.17% | ||
Current year | +9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 15-12-31 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 23-10-02 |
Simon Wallwork
SEC | Corporate Secretary | - | 21-06-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 22-01-15 |
William Paris
BRD | Director/Board Member | 73 | 21-09-21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21-09-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 11.5 | 0.00% | 0 |
24-05-09 | 11.5 | 0.00% | 8,000 |
24-05-08 | 11.5 | 0.00% | 0 |
24-05-07 | 11.5 | 0.00% | 0 |
24-05-03 | 11.5 | 0.00% | 161 |
Delayed Quote London S.E., May 10, 2024 at 02:59 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.88M | |
+23.37% | 47.02B | |
+49.90% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- BVX Stock